title: Inflammatory pre-conditioning of mesenchymal multipotent stromal cells improves their immunomodulatory potency in acute pyelonephritis in rats.
abstract: OBJECTIVE
  Acute pyelonephritis is one of the most frequent infectious diseases of the urinary tract and a leading cause of kidney failure worldwide. One strategy for modulating excessive inflammatory responses in pyelonephritis is administration of mesenchymal multipotent stromal cells (MMSCs).
  
  
  METHODS
  The putative protective effect of injection of MMSCs against experimental acute pyelonephritis was examined. We used in vivo experimental model of APN where bacteria are introduced in the bladder of rat. Three days after, intravenous injection of MMSCs was done. On the 7th day blood samples and kidneys were taken for further analysis.
  
  
  RESULTS
  We found obvious signs of oxidative stress and inflammation in the kidney in acute pyelonephritis in rats. Particularly, pro-inflammatory cytokine tumor necrosis factor-α levels, malondialdehyde, nitrite and myeloperoxidase activity were significantly increased. Histologic evaluation revealed numerous attributes of inflammation and tissue damage in the kidney. Treatment with MMSCs caused a remarkable decrease of all of these pathologic signs in renal tissue. Also, activated leukocytes induced pre-conditioning-like signaling in MMSCs. We showed alterations of expression or activity of inducible nitric oxide synthase, transforming growth factor-β, matrix metalloproteinase-2 and glycogen synthase kinase-3β, which could mediate immunomodulation and protective effects of MMSCs. This signaling could be characterized as inflammatory pre-conditioning.
  
  
  CONCLUSIONS
  The beneficial capacity of MMSCs to alleviate renal inflammation was more pronounced when pre-conditioned MMSCs were used. This approach could be used to prime MMSCs with different inflammatory modulators to enhance their engraftment and function in an immunoprotected fashion.
authors.affiliation: A. N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation. plotnikov@genebee.msu.ru
authors.forename: Egor Y
authors.initials: EY
authors.lastname: Plotnikov
authors.forename: Natalya V
authors.initials: NV
authors.lastname: Pulkova
authors.forename: Irina B
authors.initials: IB
authors.lastname: Pevzner
authors.forename: Ljubava D
authors.initials: LD
authors.lastname: Zorova
authors.forename: Denis N
authors.initials: DN
authors.lastname: Silachev
authors.forename: Maria A
authors.initials: MA
authors.lastname: Morosanova
authors.forename: Gennady T
authors.initials: GT
authors.lastname: Sukhikh
authors.forename: Dmitry B
authors.initials: DB
authors.lastname: Zorov
mesh_terms: D000208:Acute Disease / Q000628:therapy; D000818:Animals; D002450:Cell Communication; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D056747:Immunomodulation; D007249:Inflammation / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D018384:Oxidative Stress; D011704:Pyelonephritis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; C496319:NOS2 protein, human; D052247:Nitric Oxide Synthase Type II; D020778:Matrix Metalloproteinase 2